|Bid||5.90 x 900|
|Ask||5.93 x 800|
|Day's Range||5.81 - 6.04|
|52 Week Range||1.28 - 9.49|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 26, 2018 - Mar 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.33|
LONDON, UK / ACCESSWIRE / July 11, 2018 / If you want a free Stock Review on MNK sign up now at www.wallstequities.com/registration. WallStEquities.com takes a look at the Generic Drugs market, which can be segmented into biosimilars, simple generic, and super generic. Based on its therapeutics applications, the generic drugs market can be classified into cardiovascular products, anti-infective drugs, anti-arthritis drugs, central nervous system drugs, anti-cancer drugs, respiratory products, and others.Under monitoring this morning are four equities: Galectin Therapeutics Inc. (NASDAQ: GALT), Karyopharm Therapeutics Inc. (NASDAQ: KPTI), Lannett Co. Inc. (NYSE: LCI), and Mallinckrodt PLC (NYSE: MNK).
Galectin Therapeutics, Inc. (GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company has received notice of issuance of U.S. Patent Number 9,968,631 titled "Method and Treatment of Pulmonary Fibrosis.” The patent's principal claims cover method of use of GR-MD-02 as a means to treat pulmonary fibrosis. The patent is expected to provide broad protection for the use of GR-MD-02 for compositions, methods of using and methods of manufacturing compositions capable of treating pulmonary fibrosis. The patent coverage extends to 2032.
Investors need to pay close attention to Galectin Therapeutics (GALT) stock based on the movements in the options market lately.
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug is a carbohydrate drug that inhibits the galectin-3 protein that is directly involved in multiple inflammatory, fibrotic, and malignant diseases.
Galectin Therapeutics Inc’s (NASDAQ:GALT): Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease, skin disease, and cancer. The US$330.23M market-capRead More...
The first treatments for this growing epidemic of liver disease will be huge blockbusters, and one of these biotechs could have what it takes.
NEW YORK, NY / ACCESSWIRE / June 14, 2018 / Flex Pharma was one of the biggest decliners in the stock market yesterday after the company announced it would be stopping two ongoing trials due to safety concerns and that it would be eliminating 60% of its workforce. Shares of Galectin saw gains after announcing that it has chosen the company’s COO to be the new chief executive. Flex Pharma, Inc. shares took a heavy tumble in Wednesday trading, closing the day down about 75%.
Galectin Therapeutics Inc. (GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold H. Shlevin, Ph.D., currently the Company’s Chief Operating Officer (COO), has been appointed Chief Executive Officer (CEO) and President to succeed Peter G. Traber, M.D., who has tendered his resignation as President, CEO and Chief Medical Officer. Board Chairman Richard Uihlein commented, “As the Company enters this next strategic phase, we are extremely pleased that Dr. Harold Shlevin, who has been Galectin’s COO since 2012, and who has extensive healthcare leadership experience, has agreed to take on the broader role of CEO at this critical juncture. Harold has significant business development experience as an executive and will be responsible for directing and overseeing the potential partnering of our NASH Phase 3 compound.
Galectin Therapeutics Inc. (GALT), the leading developer of therapeutics that target galectin proteins, announced today that the directors elected Richard E. Uihlein as Chairman of the Board of Directors. Additionally, Kevin D. Freeman was elected Vice Chairman of the Board of Directors. “It’s a great honor to have the directors’ confidence, and, on behalf of the Board, I want to thank Dr. Marc Rubin for his tireless effort and stewardship as past Chairman, as well as in his ongoing role as a member of the Board and key committees.
LONDON, UK / ACCESSWIRE / June 1, 2018 / If you want a free Stock Review on MNK sign up now at www.wallstequities.com/registration. Ahead of today's trading session, WallStEquities.com scans Galectin Therapeutics Inc. (NASDAQ: GALT), Karyopharm Therapeutics Inc. (NASDAQ: KPTI), Lannett Co. Inc. (NYSE: LCI), and Mallinckrodt PLC (NYSE: MNK).
NEW YORK, NY / ACCESSWIRE / May 15, 2018 / Tandem shares saw an increase in their share price after an analyst at Piper Jaffray upped his price target to $13 from $8. Shares of Galectin Therapeutics also saw a rise after the company announced its plans to begin a Phase 3 clinical trial program of GR-MD-02, its galectin-3 inhibitor in Nash cirrhosis. Tandem Diabetes Care, Inc. shares closed up 25.22% yesterday but lost some of those gains in after-hours trading.
Galectin Therapeutics Inc. (GALT), the leading developer of therapeutics that target galectin proteins, announced today it is proceeding with plans for a Phase 3 clinical trial program with its galectin-3 inhibitor GR-MD-02 in NASH cirrhosis, incorporating advice and guidance obtained in a meeting with the US Food and Drug Administration (FDA). The target population of the Phase 3 clinical trial will be patients with NASH cirrhosis without esophageal varices. The primary endpoint will be chosen from two endpoints that the FDA agreed may be acceptable: The change in hepatic venous pressure gradient (HVPG), which is a measure of liver blood pressure, or the progression to esophageal varices.
NORCROSS, Ga., May 11, 2018-- Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins, today reported financial results for the three months ended March 31, 2018, ...
LONDON, UK / ACCESSWIRE / April 23, 2018 / Active-Investors.com has just released a free research report on Adamas Pharma, Inc. (NASDAQ: ADMS). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ADMS as the Company's latest news hit the wire. On April 18, 2018, the Company announced positive data from the completed Phase-3 open-label trial, EASE LID 2, assessing GOCOVRI™ (amantadine) extended release capsules for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
NEW YORK, NY / ACCESSWIRE / April 5, 2018 / After falling sharply on global trade fears in early trading Wednesday, U.S. stocks rallied to close in the green. The Dow Jones Industrial Average touched a ...
CORAL GABLES, FL / ACCESSWIRE / March 29, 2018 / The biotechnology industry continued to recover on Thursday. The market itself had one of its most volatile weeks yet as the first quarter of 2018 came ...